Feld’s appointment goes into effect on Aug. 20, 2024, as he also joins the Franklin Lakes, New Jersey–based company’s executive leadership team. He succeeds Dave Hickey, who retired from BD last month. Hickey initially announced his plan to retire in February.
BD’s new Life Sciences president joins from Danaher spinoff Veralto, where he most recently served as president of Hach, a water quality products company. Before that, he held a number of senior roles at Danaher, including SVP and GM of Cepheid Europe. He also served as president of some Danaher businesses, including Mammotome, XOS and Dover Motion.
As president of BD Life Sciences — which includes Biosciences, Diagnostics Solutions and Specimen Management — Feld’s responsibilities cover the development of smart, connected, end-to-end workflows, specimen collection and diagnostics at new care settings. The segment aims to improve the diagnosis and treatment of chronic conditions.
“Mike’s expertise in applying commercial and operational excellence principles to deliver impactful results, coupled with his experience in diagnostic solutions, position him well to lead our Life Sciences segment,” said Tom Polen, chairman, CEO and president of BD. “As we build momentum behind our BD Excellence operating system, Mike’s continuous improvement mindset will be an asset to BD as our Life Sciences team continues to drive efficiencies and meaningfully expand value for our customers, their patients and the global healthcare ecosystem.”
Feld’s appointment represents one of many leadership changes at BD over the past several months. Those include:
- A new chief medical officer who took over for the retiring Dr. William Sigmund
- A new president of Surgery after Brooke Story stepped down
- A new worldwide president of Peripheral Intervention
